Download PDF
Thromb Haemost 1972; 27(01): 063-071
DOI: 10.1055/s-0038-1649010
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Effects of Ellagic Acid upon the Rabbit Fibrinolytic System

S. G Iatridis
1   Departments of Biochemistry, School of Medicine, University of Athens, Greece, and Physiology, School of Medicine, University of North Carolina, Chapel Hill, N. C., U. S. A
,
P. G Iatridis
1   Departments of Biochemistry, School of Medicine, University of Athens, Greece, and Physiology, School of Medicine, University of North Carolina, Chapel Hill, N. C., U. S. A
› Author AffiliationsAided by Grants from the National Hellenic Research Foundation, Athens, Greece, and from the FRGS VB075 and VC228.
Further Information

Publication History

Publication Date:
29 June 2018 (online)

    Permissions and Reprints

Summary

The present investigation deals with in vivo studies of possible relations of active Hageman factor (HFa) to the problems of thrombolysis. The study is based upon animal experimentation in which 40 normal, 5 dicumarolized and 5 heparinized rabbits each received ellagic acid (Elac 10-2 M) by intravenous continuous infusion at a rate of 1 ml/min for a period of 25 min. The data suggest that the Elac infusion induced in vivo activation of HF. Streptokinase (SK) injection 25 min from the start of Elac i. v. infusion failed to induce clot lysis in blood drawn one min after its injection. The phenomenon was more prominent with low (SK 250 U or 500 U) concentrations of SK. With higher concentrations, SK-induced clot lysis activity was not affected by Elac infusion.

In dicumarolized and heparinized rabbits Elac infusion still counteracted the fibrinolysis activating effect of low concentration of SK. The possibility that the above described phenomenon was due to either hypercoagulability or to a non-specific inhibitory effect of Elac upon SK was explored and excluded.

It is concluded that HFa and SK have the same site of action. Thus it seems that HFa may block the precursor upon which SK acts by forming a complex with it. It is stressed that activation of this precursor by HFa requires a suitable surface.

 

  • References

  • 1 AlJcjaersig N, Fletcher A. P, Sherry S. The mechanism of clot dissolution by plasmin. J. clin. Invest 38: 619 1959;
    CrossrefPubMedGoogle Scholar
  • 2 Aznar J, Lopez-Borrasca A. Hageman factor in the fibrinolytic system. Lancet 01: 437 1965;
    PubMedGoogle Scholar
  • 3 De Nicola P. G, Mazzetti M. Evaluation of thrombelastography. Amer. J. clin. Path 25: 447 1955;
    PubMedGoogle Scholar
  • 4 Hellem A. J. The adhesiveness of human blood platelets in vitro. Scand. J. clin. Lab. Invest 12 (Suppl. 51) 1 1960;
    CrossrefPubMedGoogle Scholar
  • 5 Holemans R, Roberts H. R. Hageman factor and in vivo activation of fibrinolysis. J. Lab. clin. Med 04: 778 1964;
    PubMedGoogle Scholar
  • 6 Iatridis P. G, Ferguson J. H. Plasminoplastin generation test of normal HF-, PTA-, X-, PTC- and AHF-platelet-poor plasmas: Evidence that only HF-plasma has an abnormal fibrinolytic activity. Nature (Lond) 207: 1404 1965;
    CrossrefPubMedGoogle Scholar
  • 7 Iatridis S. G. Fibrinolysis and Intravascular Coagulation. Separate or associated Mechanism. (Trans. St. Moritz Conf. 1965.) Thrombos. Diathes. haemorrh. (Stuttg.) Suppl 20: 58 1966;
    PubMedGoogle Scholar
  • 8 Iatridis S. G. Ellagic acid-induced acceleration of intravascular clotting and thrombolysis. Hemostase 06: 363 1966;
    PubMedGoogle Scholar
  • 9 Iatridis S. G, Iatridis P. G, Ferguson J. H. Effects of ellagic acid upon the human fibrinolytic system. Thrombos. Diathes. haemorrh. (Stuttg) 16: 657 1966;
    PubMedGoogle Scholar
  • 10 Iatridis S. G, Iatridis P. G, Ferguson J. H. The role of HF (Factor XII) in the pathogenesis of the thrombolytic state induced by venous occlusion. Thrombos. Diathes. haemorrh. (Stuttg) 16: 207 1966;
    PubMedGoogle Scholar
  • 11 Iatridis S. G, Ferguson J. H. Effect of surface and Hageman factor on the endogenous or Spontaneous activation of the fibrinolytic system. Thrombos. Diathes. haemorrh. (Stuttg) 06: 411 1961;
    PubMedGoogle Scholar
  • 12 Iatridis S. G, Ferguson J. H. Active Hageman factor: a plasma lysokinase of the human fibrinolytic system. J. clin. Invest 41: 1277 1962;
    CrossrefPubMedGoogle Scholar
  • 13 Iatridis S. G, Ferguson J. H. Effect of physical exercise on blood clotting and fibrinolysis. J. appl. Physiol 18: 337 1963;
    CrossrefPubMedGoogle Scholar
  • 14 Nygaard K. K. A direct method of counting platelets in oxalated plasma. Proc. Mayo Clin 08: 365 1933;
    PubMedGoogle Scholar
  • 15 Ogston D, Ogston G. M, Ratnoff O. D, Forbes G. D. Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform : the participation of Hageman factor and additional cofactors. J. clin. Invest 48: 1786 1969;
    CrossrefPubMedGoogle Scholar
  • 16 Onchi K. Contact phase and fibrinolytic system. Acta haemat. jap 29: 182 1966;
    PubMedGoogle Scholar
  • 17 Ratnoff O. D, Crum J. D. Activation of Hageman factor by solutions of ellagic acid. J. Lab. clin. Med 65: 359 1964;
    PubMedGoogle Scholar
  • 18 Ratnoff O. D, Menzie G. A. A new method for the determination of fibrinogen in small samples of plasma. J. Lab. clin. Med 37: 316 1951;
    PubMedGoogle Scholar